New & Emerging Biologic Agents in CRSwNP: Pathophysiology Insights & Patient Selection Criteria Livestream #8

Join us for a livestream event!

 

Tuesday, May 24, 2022

7:00 PM – 8:00 PM ET

 

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

This educational activity is supported by an educational grant from GlaxoSmithKline.

PROGRAM OVERVIEW

Until recently, the only treatment choices for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) included saline irrigation for symptomatic relief, local or oral corticosteroids to keep inflammation under control, and polypectomy through endoscopic sinus surgery. Nasal polyposis is typically present in patients with the highest levels of disease severity, and endoscopic surgery to remove polyps is not the cure one might presume. Nearly 80% of patients who undergo polypectomy experience polyp recurrence within two years and >35% eventually opt for a second surgery. To address this, novel biologics have been and continue to be evaluated for their impact on CRSwNP, giving clinicians treatment options beyond steroids and surgery for their CRSwNP patients who are struggling to breathe freely. However, these new options necessitate education on clinical trial results for biologic therapy, criteria that should be used when choosing between biologics and surgery, and patient education in regards to treatment with biologics. These topics will be addressed by an expert faculty presenter during this initiative.

FACULTY

Michael S. Blaiss, MD, FACAAI
Clinical Professor
Medical College of Georgia at Augusta University
Augusta, Georgia

TARGET AUDIENCE

This educational program is designed for allergists, immunologists, nurse practitioners, and physician assistants who manage patients with CRSwNP.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Review the pathophysiologic/immunogenic molecular drivers of chronic rhinosinusitis that lead to the inflammatory endotypes and relevant comorbidities frequently observed in patients with CRSwNP
  • Discuss the differences between currently approved and emerging biologic treatment options for CRSwNP using data from clinical trials and other analyses
  • Incorporate an individualized, patient-centric focus based on consensus criteria for patients with CRSwNP when recommending a biologic therapy or endoscopic nasal surgery

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • View the live broadcast
  • Complete the posttest and the evaluation form at the end of the program

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Michael S. Blaiss, MD, FACAAI
Consulting Fees: ALK-Abello, Amgen, AstraZeneca, GlaxoSmithKline, Merck, Perrigo, Pfizer, Regeneron, Sanofi, TerSera​
Speakers’ Bureaus: ALK-Abello, Merck, Regeneron, Sanofi

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Agenda

On the day of the program, you may access the event by going to any of the following links:

Livestream platform: https://integrityce.com/NP8

Twitter:  https://twitter.com/SoMeCME

Facebook: https://www.facebook.com/integritycontinuingeducation

YouTube: https://www.youtube.com/channel/UC7YBDn98MBWpxHIP79JqShg

There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 1.0 AMA PRA Category 1 CME creditTM. To do so, you must participate in the virtual livestream activity and complete the posttest and evaluation following the event. A statement of credit will be issued within four weeks of submission of a completed activity evaluation form.